Develops blood tests for diagnosing a range of cancers and other diseases worldwide. Sells Nu.Q tests specifically designed for cancer detection. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Average growth of 109% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
This company is not turning a profit, so the market is pricing its sales instead: 1.5× for every dollar of annual revenue.
Against companies in its own sector, it looks cheaper than 2% of them.
No analyst target is on record for this company.
An investor who bought at the very peak is down 100% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 4 years, sales grew about 109% a year on average.
Sales run at $1.7M a year. A small number, but proof the product has real buyers.
Over the last 12 months, company executives reported 63 buys and 51 sells. Management buying with its own money is usually read as a good sign.
A loss of $23.4M against $1.7M in annual sales.
The stock sits at $0.31. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.
On our five-subject report card, VNRX sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: VNRX is a high-risk stock — not yet profitable, and its future rides on its product catching on.
Not covered, because the filings we hold do not carry it: the revenue breakdown.